What Is KLOW Peptide? A Plain-English Overview
In plain English
What is KLOW peptide? KLOW is a research blend of four separate peptides co-formulated in one vial. It is not a single molecule — it is four distinct compounds dissolved together at fixed ratios. The most common research-vial composition is 80 mg total, split as GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, and KPV 10 mg.
Here is the honest two-paragraph version. Each of the four components has its own published research record. KPV has been studied for gut anti-inflammatory activity via a specific cellular transporter. GHK-Cu, the mass-dominant component at 62.5% of the vial, has been studied for collagen synthesis and broad gene-expression modulation. BPC-157 has decades of rodent tissue-repair data and a first human IV safety study. TB-500 is a short synthetic fragment of a protein called thymosin beta-4, which has wound-healing and cardiac research data. None of the four is FDA-approved.
The key gap: no controlled study has ever tested the four-peptide KLOW blend itself — against any subset, monotherapy, or placebo. Every synergy claim is an extrapolation. The klow stack page covers the pharmacokinetics — including the four very different half-lives.
What is KLOW peptide? — component by component
KPV (Lys-Pro-Val, MW 342.44 Da, CAS 67727-97-3) is the C-terminal tripeptide of alpha-MSH (alpha-melanocyte-stimulating hormone). It is a substrate of PepT1 — the intestinal di/tripeptide transporter (SLC15A1) — with a Km of approximately 160 micromolar, giving it preferential uptake into inflamed gut epithelial and immune cells. Nanomolar KPV inhibits NF-kappaB nuclear import and reduces TNF-alpha, IL-6, IL-1beta secretion in vitro; oral KPV reduced DSS- and TNBS-induced colitis severity in mice [3].
GHK-Cu (Glycyl-L-Histidyl-L-Lysine Copper(II) complex, MW 402.92 Da, CAS 89030-95-5) is the mass-dominant component. First isolated from human plasma in 1973 by Loren Pickart; endogenous levels decline with age [4]. GHK-Cu stimulates collagen, dermatan sulfate and proteoglycan synthesis; it modulates approximately 31.2% of human protein-coding genes at the 50% threshold, with strongest signals on extracellular-matrix remodeling, antioxidant defense and DNA-repair gene sets [5]. Its blue color comes from the chelated copper(II) ion.
BPC-157 (Body Protection Compound 157, GEPPPGKPADDAGLV, MW 1419.53 Da, CAS 137525-51-0) is a synthetic 15-amino-acid peptide derived from a protein in human gastric juice. It activates VEGFR2/PI3K/Akt/eNOS angiogenesis, upregulates growth-hormone receptor in tendon fibroblasts, and accelerated recovery of a fully transected rat Achilles tendon in a landmark 2003 study [2]. Elimination half-life under approximately 30 minutes in the formal pharmacokinetic study [8].
TB-500 (Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln, MW approximately 889 Da) is the synthetic N-acetylated heptapeptide corresponding to the LKKTET actin-binding motif of thymosin beta-4. Important distinction: most wound-healing and cardiac efficacy data cited in TB-500 marketing are for the full-length native thymosin beta-4 protein, not the short fragment. The TB-500 fragment is WADA-prohibited (S2, thymosin beta-4 is named on the Prohibited List) [7][10].
The four in one vial: the 80 mg composition
The canonical research vial — 80 mg total, split 50/10/10/10 — puts GHK-Cu at the dominant position by design: approximately 62.5% of the total mass is the copper tripeptide. The remaining three components are at equal 10 mg shares.
The co-formulation rationale is mechanistic complementarity: KPV addresses inflammatory signaling, GHK-Cu addresses matrix synthesis and antioxidant programs, BPC-157 addresses angiogenesis and tendon/gut repair, and TB-500 addresses cytoskeletal-mediated wound closure. These four arms are plausibly complementary nodes of a tissue-repair cascade.
The critical complication: the four peptides have fundamentally different molecular weights (342 Da to 1419 Da) and very different pharmacokinetic profiles. BPC-157 clears in under approximately 30 minutes [8]; the tripeptides (KPV, GHK-Cu) are smaller and also clear rapidly [9]. A single co-dissolved vial cannot hold all four at matched plasma exposures. This is a structural property of the formulation, not a defect that better timing can fully resolve. See the full half-life ledger on klow stack.
What KLOW is not
Several clarifications that appear frequently in search and community discussion:
KLOW is not a GLP-1 agonist, incretin, or weight-loss compound. None of its four components is a metabolic peptide. Some online sources mislabel KLOW as a weight-management blend; this is not supported by any component study.
KLOW is not GLOW. GLOW is a three-peptide blend of GHK-Cu, BPC-157 and TB-500 — identical to KLOW minus the KPV anti-inflammatory arm. The presence of KPV is what distinguishes KLOW.
KLOW is not WOLVERINE. WOLVERINE is a different blend with its own composition.
KLOW is not FDA-approved. It is a research-only co-formulation; none of its four components is approved for human use as part of this blend. BPC-157 is FDA 503A category 2. TB-500 / thymosin beta-4 is WADA-prohibited at all times [7][10].
The KLOW research: KLOW research page covers the mechanism and findings in detail.